

Skilled in the Art: Latham Wraps Up Biotech Win

By Scott Graham

Earlier this week I reported that Janssen Biotech and a team of Latham & Watkins attorneys invalidated three patents that had been asserted against the company's \$2 billion blood cancer biologic drug Darzalex.

U.S. District Judge Leonard Stark granted summary judgment on Jan. 25. On Thursday, the parties formally settled all remaining claims, including Janssen's counterclaim for inequitable conduct.

Latham's team was led by Michael Morin, global co-chair of the firm's IP litigation practice, and partners David Frazier, Roger Chin, Max Grant and Ann Marie Wahls, plus associates Brenda Danek and Michael Seringhaus

Scott Graham focuses on intellectual property and the U.S. Court of Appeals for the Federal Circuit. He writes ALM's Skilled in the Art IP briefing. Contact him at sgraham@alm.com.